Immunovant (NASDAQ: IMVT) stock is up 97%. IMVT stock is then immediately on the market, in quantity, to recapitalise the company. This is actually a pretty common pattern in development pharma companies. Every major price rise is then met by the issuance of more stock. That’s just the way the sector works.
The reason for this is that until there’s an actual FDA approved drug then there is simply no asset within the company. No assets, no borrowing. Everything has to be funded through shareholder capital. That’s fine, it’s just the way the sector works. However, there are many potential points of failure along the way from a bright idea to an FDA approved treatment. So no one is every funded for that whole pathway. Instead funding is usually to the next potential failure point. Pass that next test, the company is worth more - hey, another potential failure avoided - and that’s when the capital is raised to attempt to pass the next test.
This is the model that Immunovant is following here. They’ve got 20 months of money already but here we are, a doubling of the stock price - great, issue more stock.
The reason for the stock price doubling: “The company tested its drug, known as IMVT-1402, in healthy adults. The experimental under-the-skin shot led to dose-dependent reductions in immunoglobulin G, or IgG. This antibody is one of the culprits behind numerous autoimmune conditions. Importantly, Immunovant said lowering immunoglobulin G levels didn't lead to an increase in "bad" LDL cholesterol or serum albumin.” That this was in healthy patients shows that this is Phase I trials, checking to see whether the drug kills healthy people. That means we’re 5 or more years away from an actual product. Phase II trials will be on ill people to see whether it actually cures, Phase III on a wider population to look at side effects. There’s considerable time to go here.

Immunovant stock price from Google Finance
That capital structure of development pharma companies though. There’s a stock issue here: “today announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock. Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering.” $170 million of that is already placed with strategic investors. What we’re not being told yet is the pricing of the issue.
Usually an issue will lead to a fall back of the elevated stock price. But given the $5 billion market cap (after this price rise) it’s not going to be too dilutive. So the price reaction might not be too large.
But this is the next test for the Immunovant stock price - the terms and size of that stock issue.



